Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA

References

• Associated Press. (1995, December 25). AIDS drugs surface on black market. New York Times, p. 43.
   Google Scholar
• Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., & Moss, A. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183. doi:10.1097/00002030-200106150-00015
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2012). Interim guidance for clinicians considering the use of pre-exposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Morbidity and Mortality Weekly Report, 61, 586–589. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm
   PubMedGoogle Scholar
• Curran, J. W., & Crosby, R. A. (2013). Pre-exposure prophylaxis for HIV: Who will benefit and what are the challenges? American Journal of Preventive Medicine, 44(1S2), S163–S166. doi:10.1016/j.amepre.2012.10.005
   PubMedGoogle Scholar
• Dennis, M. L., Titus, J. C., White, M. K., Unsicker, J. I., & Hodgkins, D. (2002). Global appraisal of individual needs – Initial (GAIN-I). Bloomington, IL: Chestnut Health Systems.
   Google Scholar
• Dorschner, J. (2005, June 30). Activists: HIV care scam uses homeless. Miami Herald, p. 1A.
   Google Scholar
• Flaherty, M. P., & Gaul, G. M. (2003, December 19). Florida Medicaid fraud costs millions, report says. Washington Post, p. E03.
   Google Scholar
• Food and Drug Administration. (2012). Truvada for PrEP fact sheet: Ensuring safe and proper use. Retrieved from http://www.fda.gov/downloads/newsevents/newsroom/factsheets/ucm312279.pdf
   Google Scholar
• Glasgow, K. (1999, October 21). The new dealers: They're poor, black, and HIV-positive. Their product? The AIDS medications intended to cure them. Miami New Times. Retrieved from http://www.miaminewtimes.com/1999-10-21/news/the-new-dealers/
   Google Scholar
• Grelotti, D. J., Closson, E. F., & Mimiaga, M. J. (2013). Pretreatment antiretroviral exposure from recreational use. The Lancet Infectious Diseases, 13(1), 10–12. doi:10.1016/S1473-3099(12)70294-3
   PubMedGoogle Scholar
• Hurt, C. B., Eron, J. J., & Cohen, M. S. (2011). Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clinical Infectious Diseases, 53(12), 1265–1270. doi:10.1093/cid/cir684
   PubMed Web of Science ®Google Scholar
• Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Burke, J. J. (2006). The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Substance Use and Misuse, 41(2), 255–264. doi:10.1080/10826080500391829
   PubMed Web of Science ®Google Scholar
• Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Cicero, T. J. (2007). Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Medicine, 8(2), 171–183. doi:10.1111/j.1526-4637.2006.00255.x
   PubMed Web of Science ®Google Scholar
• Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012). The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Annals of Internal Medicine, 156(8), 541–550. doi:10.7326/0003-4819-156-8-201204170-00004
   PubMed Web of Science ®Google Scholar
• Kippax, S. (2012). Effective HIV prevention: The indispensable role of social science. Journal of the International AIDS Society, 15(2), 17357. doi:10.7448/IAS.15.2.17357
   PubMed Web of Science ®Google Scholar
• Koenig, L. J., Lyles, C., & Smith, D. K. (2013). Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: Lessons learned from trials and treatment studies. American Journal of Preventive Medicine, 44(IS2), S91–S98. doi:10.1016/j.amepre.2012.09.047
   Google Scholar
• Krakower, D. S., Mimiaga, M. J., Rosenberger, J. G., Novak, D. S., Mitty, J. A., White, J. M., & Mayer, K. H. (2012). Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE, 7(3), e33119. doi:10.1371/journal.pone.0033119.t005
   PubMed Web of Science ®Google Scholar
• Liu, A. Y., Kittredge, P. V., Vittinghoff, E., Raymond, H. F., Ahrens, K., Matheson, T., … Buchbinder, S. P. (2008). Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. Journal of Acquired Immune Deficiency Syndrome, 47(2), 241–247. doi:10.1097/QAI.0b013e31815e4041
   PubMed Web of Science ®Google Scholar
• Mansergh, G., Koblin, B. A., Colfax, G. N., McKirnan, D. J., Flores, S. A., & Hudson, S. M. (2010). Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among us men who have sex with men. Journal of Acquired Immune Deficiency Syndrome, 55(2), e14–e16. doi:10.1097/QAI.0b013e3181f27616
   PubMed Web of Science ®Google Scholar
• Mimiaga, M. J., Case, P., Johnson, C. V., Safren, S. A., & Mayer, K. H. (2009). Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. Journal of Acquired Immune Deficiency Syndrome, 50(1), 77–83. doi:10.1097/QAI.0b013e31818d5a27
   PubMed Web of Science ®Google Scholar
• O'Grady, C., Surratt, H. L., Kurtz, S. P. (2013, June 15). Antiretroviral medication diversion in South Florida: Prescription types and motivations. Poster session presented at the 75th Annual Meeting of the College on Problems of Drug Dependence, San Diego, California.
   Google Scholar
• Philpott, S. (2013). Social justice, public health ethics, and the use of HIV pre-exposure prophylaxis. American Journal of Preventive Medicine, 44(IS2), S137–S140. doi:10.1016/j.amepre.2012.09.029
   Google Scholar
• Smith, D., Grant, R., Weidle, P., Lansky, A., Mermin, J., & Fenton, K. (2011). Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report, 60(3), 65–68. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm
   PubMedGoogle Scholar
• Surratt, H. L., & Kurtz, S. P. (2013). A national perspective on the abuse and diversion of prescription drugs. Paper presented at the Nova Southeastern University Faculty Symposium, Nova Southeastern University. Retrieved from http://arsh.nova.edu/presentations/forms/a_national_perspective_on_the_abuse_and_diversion_of_prescription_drugs.pdf
   Google Scholar
• Surratt, H. L., Kurtz, S. P., Cicero, T. J., O'Grady, C., & Levi-Minzi, M. A. (2013). Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. American Journal of Public Health, 103(6), 1026–1028. doi:10.2105/AJPH.2012.301092
   PubMed Web of Science ®Google Scholar
• Weber, J., Tatoud, R., & Fidler, S. (2010). Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: The strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS, 24(Suppl. 4), S27–S39. doi:10.1097/01.aids.0000390705.73759.2c
   PubMed Web of Science ®Google Scholar